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Aim. Compare EoE-AP with EoE-D for clinical, endoscopy (EGD), histology and outcomes and also with FAP-N. Method.
Symptoms, physical findings, EGD, histology, symptom scores, and treatments were recorded for the three groups. Cluster analysis
was done. Results. Dysphagia and abdominal pain were different in numbers but not statistically significant between EoE-AP and
EoE-D. EGD, linear furrows, white exudates were more in the EoE-D and both combined were significant (𝑝 < 0.05). EoE-D, peak
andmean eosinophils (𝑝 0.06) and eosinophilic micro abscesses (𝑝 0.001) were higher. Follow-Up. Based on single symptom, EoE-
AP had 30% (𝑝 0.25) improvement, EoE-D 86% (𝑝 < 0.001) and similar with composite score (𝑝 0.57 and <0.001, resp.). Patients
who had follow-up, EGD: 42.8% with EoE-AP and 77.8% with EoE-D, showed single symptom improvement and the eosinophil
count fell from 38.5/34.6 (peak and mean) to 31.2/30.4 (𝑝 0.70) and from 43.6/40.8 to 25.2/22.8 (𝑝 < 0.001), respectively. FAP-
N patients had similar symptom improvement like EoE-D. Cluster Analysis. EoE-AP and FAP-N were similar in clinical features
and response to treatment, but EoE-D was distinctly different from EoE-AP and FAP-N. Conclusion. Our study demonstrates that
EoE-AP and EoE-D have different histology and outcomes. In addition, EoE-AP has clinical features similar to the FAP-N group.
1. Introduction
Eosinophilic esophagitis (EoE) in children and adolescents
is associated with a variety of symptoms [1]. The consensus
recommendation identified four dominant presenting symp-
toms of esophageal dysfunction: dysphagia (D), abdominal
pain (AP), gastroesophageal reflux (GERD)/vomiting, and
failure to thrive/feeding difficulty (FTT) [2]. Historically,
GERD “evolved,” in its categorization as erosive esophagi-
tis (EE), nonerosive gastroesophageal disease (NERD), and
functional GERD [3, 4]. Clinicians know that the treatment
for EE and NERD versus functional GERD is undoubtedly
different [4, 5]. However, treatment of EoE is the same
irrespective of the dominant symptom and has not been
differentiated based on symptom.
Treatment of EoE in children includes steroids or diet.
The symptom and/or histological improvement for these
treatments vary from 50 to 100% [2] and prior studies did
not often subgroup EoE patients based on the dominant
presenting symptom. In practice, we observed that patients
with EoE-AP have less favorable outcomes with treatment
compared to EoE-D and that those children and adolescents
with EoE-AP have clinical features similar to functional
abdominal pain (FAP) except for the presence of eosinophils
in the esophagus [2, 5]. Recent clinical trials on EoE include
dysphagia as a required symptom and exclude patients who
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Table 1: Clinical features of patients with eosinophilic esophagitis and functional abdominal pain.
EoE-D 𝑛 (%) EoE-AP 𝑛 (%) FAP 𝑛 (%) EoE-D versus EoE-AP (𝑝) EoE-AP versus FAP (𝑝)
Sex (%)
Male 58 (90.6) 49 (77.8) 26 (42.6) 0.054 <0.001
Female 6 (9.4) 14 (22.2) 35 (57.4)
Mean age, yr (range) at diagnosis 11.7 (3–17) 9.44 (2–17) 10.87 (4–17)
Mean duration of FU, yr. (range) 3.4 (0.5–7.8) 5.5 (0.4–8.8) 4.8 (0.5–5.4)
Presenting symptomsa, number (%)
Dysphagia 64 (100) 1b (1.6) 0 (0) 0.00 0.50
Abdominal painc 8 (12.1) 63 (100) 61 (100) 0.00 0.07
Nausea 11 (16.7) 29 (45.3) 27 (44.3) 0.00 0.10
Vomiting 12 (18.2) 11 (17.2) 1 (1.6) 0.16 0.00
Regurgitation 5 (7.6) 7 (11.1) 3 (4.9) 0.19 0.12
Heartburn 7 (10.6) 6 (9.5) 1 (1.6) 0.21 0.05
Diarrhea 4 (6.25) 7 (11.1) 1 (1.6) 0.51 0.075
aSome patients had more than one presenting symptom.
bPatient initially presented with dysphagia; however subsequent visits showed abdominal pain as primary cause for distress.
cAbdominal pain was central or generalized.
have abdominal pain without dysphagia [6]. To better define
and characterize EoE, we divided the patients seen at our
EoE clinic into four groups based on the dominant presenting
symptom: dysphagia (EoE-D), abdominal pain (EoE-AP),
GERD (EoE-GERD), and EoE-FTT.
We hypothesized that the two groups of EoE (EoE-
D and EoE-AP) have different patterns of endoscopic and
histologic findings and response to treatment. In addition,
since EoE-AP has clinical features similar to FAP, we included
a third group of patients, FAP with normal endoscopy and
biopsy (FAP-N), for comparison [5]. Our study aims were to
compare clinical features, endoscopic and histologic features,
treatments, and outcomes of patients with EoE-AP to those
with EoE-D and compare both groups to FAP-N. Our goal
was to look for differentiating or comparable features between
these groups and to see if EoE-AP has features similar to
FAP.
2. Method
In this retrospective study, all children and adolescents with
EoE seen over a period of 2.5 years (1/2010 to 6/2012) were
divided into four groups based on the dominant presenting
symptom.
Patients with EoE-AP had central or generalized abdom-
inal pain. Diagnosis of EoE was confirmed as follows:
esophageal biopsy with 15 or more eosinophils/HPF, no
increased infiltration of eosinophils in the stomach or duode-
num, preendoscopy treatment with proton pump inhibitors
(omeprazole 40–60mg or lansoprazole 30–60mg), and/or
a negative esophageal pH study (Bravo, Given Imaging,
USA) [2, 7]. An additional cohort of children with FAP-
N was selected from those seen in the clinic during the
same time period with clinical criteria for FAP and having
a normal EGD and biopsy [5]. Patients with celiac, Crohn’s,
drug allergy, and eosinophils in the stomach or duodenum
were excluded.The following data were collected: symptoms,
physical findings, allergic diseases, CBC, CMP, ESR, U/A,
and endoscopic findings (furrows, white spots/exudates, con-
centric rings, and friability entered as absent (0) or present
(1)). Three-four biopsies were obtained from duodenum,
stomach, and distal andmid esophagus for histology. Severity
of abdominal pain, nausea, vomiting, regurgitation, and
heartburn was scored as follows: absent, 0; mild, 1 (does not
interfere with daily activities); and severe, 2 (interferes with
daily activities). A dysphagia score was assigned: absent, 0;
mild, 1; severe, 2 [6, 8]; and an additional score for food
impaction, 3, defined as impacted food requiring endoscopic
removal [9]. Peak and mean esophageal eosinophil count
at distal and mid esophagus were taken at diagnosis and
follow-up [9, 10]. The GERD (presenting with heartburn or
regurgitation without dysphagia) and FTT groups were not
included because they were not part of our hypothesis for this
study and were much smaller group.
Treatments included the following: topical steroids (fluti-
casone 880mcg/day for age 1–10 years and 1760mcg/day for
11–18 years, in four divided doses or budesonide 0.5mg BID
for patients up to 5 feet tall and 1mg BID for those over 5
feet) and six food elimination or directed diet based on the
allergy tests, [11, 12] based on a collaborative decision by the
physician and family [12–14]. In some patients, a combination
of diet and topical steroids was used. Clinical outcome was
measured as follows: for dysphagia and abdominal pain as
improved (score decreased by 1 or more), worsened (score
increased by 1 or more), and no change (score same) and as
composite score (calculated from the commonfive symptoms
for each patient, given in Table 1, and then as a sum for all
patients for each group), at diagnosis and follow-up [6, 8,
9]. EGD score and eosinophil count (peak and mean) were
compared by comparing first endoscopy and the follow-up
endoscopy [6, 9, 13, 14]. Statistical analysis was done using
SPSS version 20. Significant 𝑝 value was <0.05. For symptom
outcome scores, a test of hypothesis was done by two-tailed
binominal test. Institutional Review Board approval for this
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study was obtained through Advocate Health Care (Oak
Brook, IL).
3. Data Analysis
Presenting symptoms and signs, associated allergic diseases,
and treatments offered were entered into a two-step cluster
analysis to determine whether there were distinct clusters
[15]. These clusters were then cross-tabulated with the
three groups of patients to determine whether the different
groups of patients could be distinguished by clinical features.
These are the following: age, abdominal pain, dysphagia,
nausea, vomiting, regurgitation, anorexia, nocturnal awak-
ening, early satiety, constipation, diarrhea, allergic rhinitis,
eczema, asthma, PPI use, fluticasone, budesonide, and diet.
In addition, a discriminant function analysis was performed
to further explore clinical features associated with the three
patient groups. Cross-tabulation with chi-square test was
used to compare clinical outcomes across the three groups.
Within each group, cross-tabulations and chi-square tests
were used to examine the impact of treatment choices (oral
steroid, directed diet, elemental diet, and other medications)
on clinical outcomes [15].
4. Results
Patient characteristics by condition are shown in Table 1.
Other than the dominant symptom, clinical features were
similar in the two EoE groups. Nausea was seen more
frequently in the EoE-AP and the clinical features of EoE-
AP were similar to the FAP-N. Of the total 64 patients in
EoE-D and 63 in EoE-AP group, 59 and 58, respectively, had
PPI treatment and the remainder (10 patients out of study
population of 127) had normal pH study.ThemeanWBCwas
5320/mm3, 5420/mm3, and 4930/mm3 in the EoE-D, EoE-AP,
and FAP groups. Eosinophil count more than 350/mm3 was
18.6%, 12.9%, and 6.2% in the three groups. ESR was done in
4/64 EoE-D patients and all patients with EoE-AP and FAP
and was normal in all groups. EGD and biopsy findings are
noted in Table 2. Visual EGD findings of the esophagus were
more apparent in the EoE-D group, particularly the linear
furrows and white exudates, and differences were statistically
significant. When these two findings were combined, the
differences increased and remained significant. Peak and
mean eosinophil counts were as follows: EoE-D, 43.1 and
21.6; EoE-AP, 38.6 and 15.2 (𝑝 0.06). Other histological
features were not significant except for higher eosinophilic
microabscess (𝑝 0.001) in the EoE-D group.
5. Treatment and Outcomes
Treatments given are as follows: for EoE-D group, 45 (66.7%):
topical steroids (43 fluticasone and 2 budesonide), six (9.3%):
diet, nine (14.1%): topical steroids and diet, and two (3.1%): no
treatment; for EoE-AP group, 37 (58.7%): topical steroids (35
fluticasone and 2 budesonide), two (3.2%): diet, 21 (33.3%):
combination, and three (4.8%): no treatment. EoE-D group
received more topical steroids while EoE-AP group received
more of combined therapy with topical steroids and diet
Table 2: EGD and biopsy findings of patients.
EoE-D EoE-AP 𝑝
EGD alterations, number (%)
Linear furrows/vertical lines 53 (82.8) 33 (51.6) 0.008
White exudates 35 (54.7) 16 (25.4) 0.003
Linear furrows and white exudates 30 (46.9) 9 (14.3) <0.001
Concentric rings/trachealization 6 (9.4) 3 (4.8) 0.16
Tears/crepe paper appearance 4 (6.3) 0 0.06
Eosinophil count peak/mean 43.1/21.6 38.6/15.2 0.06
Biopsy changes, number (%)
Eosinophilic microabscesses 23 (35.9) 6 (9.5) 0.001
Basal epithelial hyperplasia 22 (34.4) 17 (27) 0.093
Papillomatosis 10 (15.6) 12 (19) 0.154
Spongiosis 9 (14.1) 10 (15.9) 0.176
FAP: visual changes and biopsies on EGD were normal.
(chisq(9) = 18.4, 𝑝 = 0.03). Follow-up period was up to 7.8
years (mean 3.4) in EoE-D, 8.8 years (mean 5.5) in EoE-AP,
and in FAP 5.4 years (mean 4.8).
Table 3 shows that subjects with EoE-D had a significant
improvement (86%) in their dominant symptom compared
to EoE-AP (30%). Table 4 shows similar results for composite
symptom score. On the contrary, composite scores worsened
in the EoE-AP group compared to EoE-D (𝑝 < 0.003). The
test of hypothesis by the two-tailed binominal test for EoE-AP
symptom outcome score showed worsening symptoms more
often than 50% of the time compared to EoE-D and this was
significant (𝑝 < 0.003); that is, the 69.8% not improved in
symptoms in the EoE-AP group is higher than the 50% and
significant. The FAP-N group improvement was similar to
EoE-D group (Tables 3 and 4).
EGD Findings. 36/64 (56.3%) subjects with EoE-D and 28/63
(44.4%) with EoE-AP had follow-up endoscopy and biopsies
with same protocol, done after 8–12 weeks of treatment
(Table 5). Of the 36 subjects with EoE-D, 28/36 (77.8%)
improved based on dysphagia, and the eosinophil count
at diagnosis was 43.2/40.1 (peak/mean) and 25.8/22.7 at
follow-up. This improvement was statistically significant and
showed a linear correlation of eosinophils with the symptom
improvement. For EoE-AP, 12/28 improved (42.8%) based on
AP and the eosinophil count was 38.2/34.6 (peak/mean) and
at follow-up 31.4/32.6 and did not have a linear correlation
like EoE-D nor had a statistically significant difference in
the eosinophils. In subjects who did not have follow-up
endoscopy, 27/28 (96.4%) subjects with EoE-D and 7/35
(20%) of thosewith EoE-AP improved based on the dominant
symptom.
Figure 1 shows a histogram of the distribution of scores
on the discriminant function with patient groups. EoE-AP
and EoE-D subjects are perfectly discriminated, but EoE-AP
subjects are both difficult to distinguish from FAP-N subjects
(that is, they have similar features) and highly (though not
perfectly) discriminable from EoE-D subjects.
Cluster analysis identified two clusters of patients with
fair fit quality (average silhouette measure 0.4). Cluster 1
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Table 3: Symptom score change, dysphagia for EoE-D and abdominal pain for EoE-AP and FAP, baseline versus follow-up.
EoE-D EoE-AP FAP EoE-D versus EoE-AP (𝑝) EoE-AP versus FAP (𝑝)
Total, number (%) 64 63 61
Improved 55 (85.9) 19 (30.2) 49 (80.3) <0.001 <0.001
Not improved 9 (14.1) 44 (69.8) 12 (19.7)
EoE-D: baseline mean score = 1.5; sd = 0.69. Follow-up mean score = 0.6; sd = 0.53.
Mean difference is −0.89, which is significant (𝑝 < 0.001) by paired 𝑡-test.
EoE-AP group: baseline mean score = 1.2; sd = 0.43. Follow-up mean score = 1.4; sd = 0.77.
Mean difference is 0.20, which is not significant (𝑝 = 0.25) by paired 𝑡-test.
Table 4: Composite symptom score∗ change, baseline versus follow-up.
EoE-D EoE-AP FAP
Patients 64 63 61
Baseline score 156 129 152
Follow-up score 47 135 79
Composite score improved Score worsened Score improved
∗Symptoms included the following: dysphagia, abdominal pain, nausea, regurgitation, and vomiting.
EoE-D: baseline mean score = 2.4; sd = 0.92. Follow-up mean score = 0.7; sd = 0.67.
Mean difference is −1.68, which is significant (𝑝 < 0.001) by paired 𝑡-test.
EoE-AP: baseline mean score = 2.0; sd = 0.8. Follow-up mean score = 2.1; sd = 1.08.
Mean difference is 0.10, which is not significant (𝑝 = 0.57) by paired 𝑡-test.













FU EGD 36/64 patients 28 (77.8%) 8 (12.2%) 28/63 patients 12 (42.8%) 16 (57.2%)
Eos; peak/mean 43.6/40.8 25.2/22.8 64.6/56.6 38.5/34.6 31.2/30.4 59.5/49.5
NO FU EGD 28/64 patients 27 (96.4%) 1 (3.6%) 35/63 patients 7 (20%) 28 (80%)
∗FU: 36 (D) and 28 (AP) had follow-up EGD. Improvement based on single symptom score.
EoE-D group (𝑛 = 35): eosinophils baseline mean = 45.0; sd = 23.5. Follow-up mean = 17.7; sd = 20.3. Mean difference = −27.3; sd diff = 29.1, 𝑝 < 0.001 by
paired 𝑡.
EoE-AP group (𝑛 = 27): eosinophils baseline mean = 34.1; sd = 16.5. Follow-up mean = 32.0; sd = 32.0. Mean difference = −2.1; sd diff = 28, 𝑝 = 0.7, not
significant by paired 𝑡.
∗FU: follow-up.
included all patients with EoE-AP and FAP and eight patients
with EoE-D. Cluster 2 included the remaining 57 patients
with EoE-D and no others. The most important predictors
of cluster membership for EoE were the predominant pre-
senting symptom, abdominal pain (Cluster 1) or dysphagia
(Cluster 2). Food bolus was the next most important predic-
tor; no patients in Cluster 1 had food bolus, while 37% of
subjects in Cluster 2 had food bolus. Other symptoms were
less predictive of cluster membership. In addition, Figure 1
shows the distribution of scores on the discriminant function
with subject groups indicated by different shades. EoE-AP
and EoE-D subjects are perfectly discriminated; that is, they
are different groups. But EoE-AP subjects were difficult to
distinguish fromFAPpatients (i.e., they have similar features)
and highly (though not perfectly) discriminable from EoE-D
patients. No specific treatments were associatedwith a greater
rate of improvement overall or among groups.
6. Discussion
The diagnosis of EoE was established based on the pres-
ence of increased eosinophils in the esophagus, absence
of eosinophils in the duodenum and stomach, and the
presenting symptom. Thus eosinophilic gastroenteropathy
was excluded and only a minority of patients had diarrhea.
Our study raises the question whether EoE-AP and EoE-
D are one disease with different features and outcomes or
two different disease processes. To answer this question,
we examined differentiating factors between the two groups
including demographics, symptoms, visual endoscopic find-
ings, and eosinophils in the esophagus. Of these variables,
the features statistically significant were nausea in EoE-AP,
visual endoscopic findings, especially when white exudates
and furrows were combined, and eosinophilic microabscess
for EoE-D.



























With almost similar treatments, the EoE-D group showed
a better and statistically significant improvement of the dom-
inant symptom, while those with abdominal pain (EoE-AP)
did not, and moreover the composite score in EoE-AP group
worsened. Notably, in the EoE-D group (Table 5) there was
a linear correlation with symptom and eosinophil improve-
ment. Similar correlation was not seen with the EoE-AP.
EoE-D group received topical steroids alone while the EoE-
AP group was more likely to receive combined therapy with
topical steroids and diet, and this may be because the EoE-AP
group hadmore failures requiring additional therapy.Though
the treatments were not controlled, individual treatments
did not show an overall improvement among EoE groups,
as shown on cluster analysis, which may be a surrogate of
controlled treatment.The symptomatic improvement of EoE-
D was similar to FAP while the clinical features of EoE-AP
were similar to FAP except the eosinophils, and this raises the
question whether EoE-AP and EoE-D are different or there is
an overlap between EoE-AP and FAP.
According to the consensus recommendations, the diag-
nosis of EoE, in addition to eosinophils, should include symp-
toms of esophageal dysfunction [2].While dysphagia is a car-
dinal symptom of esophageal dysfunction, abdominal pain
does not hold a similar status as many other gastrointestinal
diseases including FAP have abdominal pain as a primary
symptom [16, 17]. Pentiuk et al. [18] looked at the correlation
of symptom score and improvement in the eosinophils before
and after treatment in 34 children and, in this group, about
70% had abdominal pain as the main symptom. Among 20 of
these 34 children in histological remission, 17 (58%) contin-
ued to report symptoms and the majority of these patients
had abdominal pain. In addition, there was no significant
difference in the frequency and severity score of abdominal
pain in patients in histological remission versus histologically
active. The authors concluded that, despite improvement in
the eosinophil count, a simultaneous symptom improvement
failed to occur. A striking observation was that the majority
of patients with this dissociation had abdominal pain as the
dominant symptom [19]. Aceves et al. [8] found a direct
correlation in improvement with dysphagia and early sati-
ety/anorexia and eosinophil count, but there was not a similar
correlation for other symptoms including abdominal pain.
Another study by Assa’ad et al. [14] on 89 children with EoE
showed a histological improvement on eosinophil numbers
but the study did not mention the symptom follow-up.These
studies note that EoE patients with abdominal pain as main
symptom have less favorable outcome with treatment. Unlike
children, adult patients present primarily with dysphagia and
not abdominal pain.One explanation for this is that, in adults,
EoE is more of a fibrostenotic disease, while in children it is
often inflammatory. Additionally there is an understanding
that the symptoms in children are “evolving,” and as they
age dysphagia is seen in older children while abdominal pain
is seen in younger children [2, 7], or it is possible that the
esophageal inflammation in EoE-AP is an incidental finding.
Could there be another reason for the poor outcome
in EoE-AP patients? Harris et al. [19] showed that a sig-
nificant number of children and adolescents with EoE have
psychosocial issues. The main symptoms of the 64 children
in this EoE study were pain/physical discomfort (56%) or
feeding/eating/appetite difficulties (45%); dysphagia was not
mentioned as a symptom. About 30% of the patients had
depression, 40% had anxiety, and about 60% had social
issues. This study, unlike ours, did not group the patients by
dysphagia or abdominal pain and suggested that EoE patients
have psychosocial issues [19], which may explain the poor
outcome in EoE-AP patients, which supports that there could
be a functional component to the EoE-AP group.
A recent large prospective study by Butz et al. looked at
the use of topical fluticasone versus placebo in a group of
children and young adults with EoE [20]. Seventy percent of
patients showed a complete remission of eosinophils at the
end of three-month treatment compared to no subjects in
placebo group. 69% of patients in the treatment group had
abdominal pain and early satiety at the start of the study.
Interestingly abdominal pain persisted in 61% of patients at
the end of the study. This study clearly demonstrated that, in
spite of histological improvement, there was no symptomatic
improvement in the abdominal pain, further evidence that
EoE-AP has a poor outcome.
Could there be other explanations for the EoE-AP pa-
tients to have a poor outcome? Talley et al. showed a positive
correlation between functional gastrointestinal disease where
the chief complaint is abdominal pain and associated duo-
denal eosinophilia [21]. Another study, related to this, but in
children, showed similar correlation of dyspeptic symptoms
and duodenal eosinophilia [22]. These studies suggest the
possibility that eosinophils in the duodenum may be related
to dyspeptic symptoms similar to FAP or visceral hyperal-
gesia. The biopsies of our patients did not have eosinophils
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in the duodenum or antrum, as the diagnosis will change
to eosinophilic gastroenteropathy and this was an exclusion
criteria as well. We also know that infection with resulting
inflammation in the gut can lead to functional gastrointesti-
nal symptoms or postinfectious functional dyspepsia (FD)
or irritable bowel syndrome [23]. Various explanations are
given for postinfectious FD-irritable bowel syndrome (IBS).
The symptoms may depend on the type of infection and/or
the site of infection, which affects the enteroendocrine cells
and inflammatory cells like macrophages, eosinophils, and
mast cells leading to altered motility. Can this explana-
tion apply to EoE-AP patients? Eosinophil granules contain
crystalloids composed of major basic protein, eosinophil-
derived neurotoxin, eosinophil cation protein, and eosinophil
peroxidase which release cytokines and chemokine, which
alters smooth muscle function. In addition, eosinophil-
derived products, leukotrienes, platelet-activating factor, and
interleukin-13, can induce smoothmuscle activation and pro-
liferation resulting in inflammation, narrowing, or motility
change [24, 25].These in vitro studies speculate that a similar
mechanism may apply to human beings. While it is possible
that thesemechanismsmay apply to EoE-APwith esophageal
eosinophil inflammation resulting in visceral hyperalgesia,
it also questions whether a proximal esophageal inflam-
mation would result in a distal dysmotility and abdominal
pain.
In addition to the clinical features, we examined if the
cluster analysis would differentiate the two groups [15].
Cluster analysis is a multidimensional scaling that seeks to
group items (signs and symptoms) into a small number of
clusters based on stronger associations between an item and
the center of its cluster of items than between an item and the
center of another cluster. The goodness of fit of the clusters is
measured by the ability to interpret their membership as well
as by the “silhouette” measure of the average distance from
each item to its cluster center compared with the center of the
next closest cluster. Silhouette scores range from −1 to 1, with
scores above 0.2 being “fair” fit to the cluster structure and
scores above 0.5 representing good fit to the cluster structure
and our analysis showed that the silhouette scores for the
two clusters were 0.4, closer to good fit. But cluster analysis
only works with clinical features; it does not account for
endoscopic results, the defining test for EoE. Both cluster
analysis including “silhouette” measure and discriminant
function grouped the EoE-AP and FAP-N as one group and
different from EoE-D.
This is among the first studies to subgroup EoE in chil-
dren and examine the clinical, endoscopic, and histological
features and outcome of the two predominant groups of
EoE and show that EoE-AP patients have poor outcomes
and have features similar to FAP. Limitations of this study
include the following: retrospective design, absence of vali-
dated symptom measures (though these scales were used in
previously published studies) [8–11], not standardizing the
dietary treatment, PPI use [26], and not correlating the exact
treatment with outcomes. In addition, within the EoE-AP
group, though the patients did not have overt dysphagia, it is
possible, but less likely, that theymay have adapted to gradual
coping mechanisms and so dysphagia was not obvious.
In conclusion, because EoE is a clinicopathological condi-
tion, histology is but one feature and should not be considered
diagnostic on its own. Our study presents evidence to suggest
that EoE-AP and EoE-D have different outcomes and the
EoE-AP grouphas features similar to FAP.Wepropose that, in
the management of EoE-AP group of patients, if optimal diet
or pharmacotherapy does not lead to symptomatic improve-
ment or when there is dissociation between histological
and symptomatic improvement, it is worth relooking not
only at adherence to diet and/or medications but also at
managing the EoE-AP group with methods successful in
functional abdominal pain patients. This in fact may help
better prognosticate the EoE-AP patients.
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